# BPC-157: The Stable Gastric Pentadecapeptide, Read as a Research Console > BPC-157, the stable gastric pentadecapeptide, accelerated tissue repair across thirty-plus preclinical studies through a VEGFR2-Akt-eNOS angiogenic mechanism. A cited research console of the pathway, the pharmacokinetics, and the human-data gap. One best-characterized angiogenic pathway, a measurable pharmacokinetic spine, a fan of per-kilogram rodent doses, and a stark human-data gap of three small pilots. Every figure on this console maps to a cited study. ## What the BPC-157 record reads out BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. Across more than thirty preclinical studies it has accelerated tissue repair — tendon, ligament, gut, nerve, and vascular — most consistently through angiogenesis, the formation of new blood vessels [1][3]. This console reads that record the way an instrument panel reads a system: each pathway leg as a channel, each datum as a figure, and the honest gap where the data stops. The identity is fixed. Molecular formula C62H98N16O22, molecular weight 1419.53 Da, CAS 137525-51-0, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val [1]. The mechanism is well-mapped: up-regulation and internalization of the VEGFR2 receptor feeding Akt then eNOS, the nitric-oxide arm of vascular repair [3]. The pharmacokinetics are characterized: linear PK, an elimination half-life under 30 minutes, intramuscular bioavailability around 14-19% in rats and 45-51% in dogs [2]. The gap is equally fixed, and this console surfaces it the way a platform flags a degraded metric. As of 2025 reviews, only three small human pilot studies exist — a two-person intravenous safety pilot, a twelve-patient intravesical interstitial-cystitis pilot, and an intra-articular knee-pain case series [10][12][14]. Rigorous, large-scale, controlled human efficacy trials are lacking [12]. BPC-157 is not an FDA-approved drug, and the [BPC-157 legal status and FDA 503A category](/legal-status) sits under active regulatory evaluation. The panels that follow read the record one channel at a time: [what the research shows](/research) across tendon, gut, vascular, and nerve models; the mechanism behind it; the studied dose context; and [side effects and safety](/faq) framed against that small human dataset. ## BPC-157 Peptide: A Stable Gastric Pentadecapeptide The BPC-157 peptide is called a stable gastric pentadecapeptide because it is reported to remain intact in human gastric juice — the property that distinguishes it from most peptides, which degrade in the gut [4]. "Pentadecapeptide" names the fifteen-amino-acid length; "stable gastric" names that resistance to gastric breakdown. Together they explain why a fragment of a gastric-juice protein became a research molecule in its own right. BPC-157 is synthetic. It is built to the BPC sequence rather than harvested, and it does not circulate as a free peptide in the body. Research suppliers commonly distribute it as the acetate salt; the literature's standard descriptor throughout is "stable gastric pentadecapeptide" [1][4]. That stability is the engine behind interest in oral and peroral administration, and intragastric dosing has been used in animal work [4]. The caveat the console holds open: formal human oral pharmacokinetics are not established, so the stable-in-gastric-juice property is a starting point, not a demonstrated oral bioavailability. The [oral vs injectable administration](/dosage) question is taken up in detail on the dosage page. ## The angiogenic mechanism, in one channel If the BPC-157 record has a single unifying line, it is pro-angiogenic cytoprotection. The peptide up-regulates VEGFR2 expression and promotes the receptor's internalization, activating the VEGFR2-Akt-eNOS pathway and raising vessel density in vivo and in vitro; blocking endocytosis blocks the effect [3]. Around that spine sit corroborating routes — Src-Caveolin-1-eNOS vasomotor modulation [9], FAK-paxillin signaling that drives fibroblast outgrowth [5], growth-hormone-receptor up-regulation in tendon fibroblasts [6], and modulation of serotonergic and dopaminergic systems [8]. The pharmacokinetic figure is the one that disciplines the rest. With an elimination half-life under 30 minutes, the parent peptide clears the blood quickly [2]. Any sustained tissue-repair effect therefore reflects downstream biology — the angiogenic cascade it sets off — not a persistent circulating level. The full [BPC-157 mechanism of action](/mechanism) breaks each leg into its own panel, with [the VEGFR2-Akt-eNOS pathway](/mechanism) as the lead channel and [pharmacokinetics and half-life](/mechanism) as the spine. ## What does BPC-157 do in the body? In animal models BPC-157 acts as a cytoprotective peptide whose repair effects are most consistently linked to angiogenesis. The best-characterized route is up-regulation and internalization of VEGFR2 with downstream Akt-eNOS nitric-oxide signaling [3]. Reported effects span gastric-ulcer protection [4], tendon, ligament, and bone healing [1], nerve regeneration [7], and organ protection — almost entirely in rodents. ### Is BPC-157 a growth hormone? No. BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of a human gastric-juice protein, not a growth hormone. It does up-regulate the growth-hormone receptor in tendon fibroblasts at the mRNA and protein level in cell culture, which sensitizes those cells to growth-hormone-driven proliferation [6] — an indirect interaction, not growth-hormone activity itself. --- A liquid-glass console reading of the peer-reviewed BPC-157 record — each datum refracted back to its source, the human-data gap left lit, and no clinic behind the panel.